CytomX Therapeutics IPO

10/8/2015

IPO

$80,000,000

This offering is intended to provide funding through first-in-human studies of our two lead programs. In particular, we currently expect to use the net proceeds from this offering as follows: approximately $25.0 million to $35.0 million for the development of CX-072, including our planned Phase 1 clinical trials and product candidate manufacturing; approximately $15.0 million to $20.0 million for the development of our Probody therapeutic directed against CD-166, including our planned Phase 1 clinical trials and product candidate manufacturing; and approximately $25.0 million to $35.0 million for research and development activities, including discovery of additional cancer immunotherapies and first-in-class therapeutics directed against difficult-to-drug targets and continued development of our Probody technology platform. We expect to use the remainder of the net proceeds from this offering for working capital and other general corporate purposes, which may include funding for the hir

Publicly-held

Biopharmaceutical

151 Oyster Point Blvd. 400
San Francisco, CA 94080
USA

CytomX (NASDAQ: CTMX) is unlocking the potential of antibody therapeutics in oncology by developing a novel therapeutic antibody class of highly targeted Probody therapeutics.